Older adults want to cut back on medication, but study shows need for caution
More than 82% of Americans age 50 to 80 take one or more kinds of prescription medication, and 80% of them say they’d be open to stopping one… read more.
More than 82% of Americans age 50 to 80 take one or more kinds of prescription medication, and 80% of them say they’d be open to stopping one… read more.
A nationwide study found a marked increase in new GLP-1RA prescriptions over the last decade, particularly since 2020. Semaglutide was the most prescribed GLP-1RA, by far, in 2023…. read more.
A large retrospective analysis of the cognitive effects of various antidiabetic treatments has disclosed that the risks of dementia and Alzheimer’s disease (AD) were significantly lower in patients… read more.
Combination treatment of diabetes with a sodium glucose co-transporter 2 inhibitor (SGLT2) and a glucagon-like peptide-1 receptor agonist (GLP1-RA) appears to also offer protection against heart and kidney… read more.
A new study led by investigators from Mass Eye and Ear found that patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss had a higher risk of… read more.
A new observational study reported for the first time a potential link between Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision… read more.
Scientists have identified a gene which, when missing or impaired, can cause obesity, behavioural problems and, in mothers, postnatal depression. The discovery, reported today in Cell, may have wider… read more.
Novo Nordisk’s weight-loss drug Wegovy has been approved for sale in China, opening the door to a huge market in which obesity rates have more than doubled among… read more.
Systematic reviews* of medical literature between 2020 to 2024 show bariatric surgery, also known as metabolic or weight-loss surgery, produces the greatest and most sustained weight loss compared… read more.
Individuals treated with anti-obesity medications generally experience reduced appetite, which typically leads to reduced food intake. As a result, dietary quality becomes more important because nutritional needs must… read more.
Your weekly digest of the top healthcare stories, covering news published from 03/06/2024 – 07/06/2024. The Guardian Researchers have discovered a major driver of inflammatory bowel disease and… read more.
Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals A pioneering… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.